Breakthrough Trial Demonstrates Bioequivalence and Potential for Enhanced Patient Compliance with Fixed-Dose Combination Therapy for Pulmonary Arterial Hypertension
Stella Richards A new phase I study has concluded that the fixed-dose combination (FDC) of ambrisentan and…
Read More